# US 2008/0306002 A1 · Combination Therapy for Preventing Angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306002 A1
- Document ID: US20080306002A1
- Status: Published application
- Kind: A1
- Application number: 12/063,071
- Filed: 2006-08-18
- Published: 2008-12-11
- Earliest claimed: 2005-08-18
- Assignees: The General Hospital Corporation
- Inventors: Daniel C. Chung; Yusuke Mizukami
- Web page: https://patentgrep.com/patent/US20080306002A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to a combination therapy for inhibiting angiogenesis in a subject having, or at risk of having, an angiogenic disease/disorder. The method comprises both administering to the mammal an inhibitor of HIF-I and administering a second compound or agent that inhibits angiogenesis such as an inhibitor of IL-8, VEGF, angiopoietins, EGF, FGF, TGF, G-CSF, or PDGF. Administration of an inhibitor of hypoxia inducible factor-1 (HIF-I) in combination with an inhibitor of interleukin 8 (IL-8) is particularly useful for treatment of colon cancer, lung cancer, pancreatic cancer, and breast cancer.

## Claims

### Claim 1

A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, an angiogenic disease or disorder by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject a second anti-angiogenic agent wherein the second anti-angiogenic agent is an inhibitor of an angiogenic agent selected from the group consisting of: vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF), granulocyte colony stimulating factor (GCSF), angiopoietin 1, and interleukin 8 (IL-8).

### Claim 2 (depends on 1)

The method of claim 1, wherein said inhibitor of hypoxia inducible factor-1 (HIF-1) and said second agent are administered simultaneously.

### Claim 3 (depends on 1)

The method of claim 1, wherein said angiogenic-disease or disorder is cancer.

### Claim 4 (depends on 4)

The method of claim 4, wherein said cancer is colon cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein said angiogenic disease is retinopathy of prematurity, diabetic retinopathy or macular degeneration.

### Claim 6 (depends on 1)

The method of claim 1, wherein said angiogenic disease or disorder is arthritis or rheumatoid arthritis.

### Claim 7 (depends on 1)

The method of claim 1, wherein said angiogenic disease or disorder is psoriasis.

### Claim 8

A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, cancer by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject an inhibitor of interleukin 8 (IL-8), wherein said cancer is selected from the group consisting of colon cancer, pancreatic cancer, lung cancer, and breast cancer.

### Claim 9 (depends on 1, 8)

The method of claim 1 or 8, wherein said combination therapy is conducted in conjunction with chemotherapy.

### Claim 10 (depends on 1, 8)

The method of claim 1 or 8, wherein said combination therapy is conducted in conjunction with radiation therapy.

### Claim 11 (depends on 1, 8)

The method of claim 1 or 8, further comprising administration of a third anti-angiogenic agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the third anti-angiogenic agent is an inhibitor of an angiogenic agent selected from the group consisting of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF), granulocyte colony stimulating factor (GCSF), and angiopoietin 1.

### Claim 13 (depends on 1, 8)

The method of claim 1 or 8, wherein said administering in steps i) and ii) comprises intravenous, intramuscular, subcutaneous, intradermal, topical, intraperitoneal, intrathecal, intrapleural, intrauterine, rectal, vaginal, intrasynovial, intraocular/periocular, intratumor or parenternal administration.

### Claim 14 (depends on 1, 8)

The method of claim 1 or 8, wherein said agents are administered prophylactically.

### Claim 15 (depends on 1)

The method of claim 1, wherein said risk for developing an angiogenic disease or disorder is determined genetically or by measuring levels of cancer marker protein.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer marker protein is selected from the group consisting of; calcitonin, PSA, thymosin β-15, thymosin β-16, and matrix metalloproteinase (MMP).

### Claim 17

A method of treating undesired angiogenesis in a tissue of a subject having, or at risk of having, an angiogenic disease or disorder by use of a combination therapy comprising i) administering to said subject an inhibitor of hypoxia inducible factor-1 (HIF-1) and ii) administering to said subject a second anti-angiogenic agent wherein the second anti-angiogenic agent is a direct angiogenesis inhibitor selected from the group consisting of: endostatin, angiostatin, thrombospondin and tumstatin.

### Claim 18

A kit designed for treatment of a subject having, or at risk of having, an angiogenic disease or disorder comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and at least one other anti-angiogenic agent, wherein the anti-angiogenic agent is selected from the group consisting of: an inhibitor of IL-8, an inhibitor of vascular endothelial growth factor (VEGF), an inhibitor of angiopoietin 1, an inhibitor of epidermal growth factor (EGF), an inhibitor of platelet derived growth factor (PDGF), an inhibitor of fibroblast growth factor (FGF), an inhibitor of transforming growth factor (TGF), and an inhibitor of granulocyte colony stimulating factor (G-CSF).

### Claim 19 (depends on 18)

The kit of claim 18, comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and an inhibitor of IL-8.

### Claim 20 (depends on 18)

The kit of claim 18, comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and an inhibitor of platelet derived growth factor (PDGF).

### Claim 21 (depends on 19)

The kit of claim 19, further comprising an inhibitor of vascular endothelial growth factor (VEGF).

### Claim 22 (depends on 19)

The kit of claim 19, further comprising an inhibitor of platelet derived growth factor (PDGF).

### Claim 23

A kit designed for treatment of a subject having, or at risk of having, an angiogenic disease or disorder comprising an inhibitor of hypoxia inducible factor-1 (HIF-1) and at least one other anti-angiogenic agent, wherein the anti-angiogenic agent is selected from the group consisting of endostatin, angiostatin, thrombospondin, and tumstatin.
